225 related articles for article (PubMed ID: 27538585)
41. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
[TBL] [Abstract][Full Text] [Related]
42. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
[TBL] [Abstract][Full Text] [Related]
43. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis.
Chauffier K; Salliot C; Berenbaum F; Sellam J
Rheumatology (Oxford); 2012 Jan; 51(1):60-8. PubMed ID: 21515629
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
[TBL] [Abstract][Full Text] [Related]
45. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
46. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study.
Kyburz D; Gabay C; Michel BA; Finckh A;
Rheumatology (Oxford); 2011 Jun; 50(6):1106-10. PubMed ID: 21258051
[TBL] [Abstract][Full Text] [Related]
47. The importance of early treatment for the prognosis of rheumatoid arthritis.
Kyburz D; Finckh A
Swiss Med Wkly; 2013; 143():w13865. PubMed ID: 24089023
[TBL] [Abstract][Full Text] [Related]
48. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
[TBL] [Abstract][Full Text] [Related]
49. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.
Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; Blåfield H; Hakola M; Sokka T
J Rheumatol; 2007 Feb; 34(2):316-21. PubMed ID: 17183623
[TBL] [Abstract][Full Text] [Related]
50. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins.
Graudal N
Scand J Rheumatol Suppl; 2004; 118():1-38. PubMed ID: 15180092
[TBL] [Abstract][Full Text] [Related]
51. Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort.
Verstappen M; Matthijssen XME; van der Helm-van Mil AHM
Rheumatology (Oxford); 2022 Aug; 61(8):3212-3222. PubMed ID: 34850952
[TBL] [Abstract][Full Text] [Related]
52. Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
Shimizu T; Choi HJ; Heilmeier U; Tanaka M; Burghardt AJ; Gong J; Chanchek N; Link TM; Graf J; Imboden JB; Li X
Arthritis Res Ther; 2017 Oct; 19(1):222. PubMed ID: 28978352
[TBL] [Abstract][Full Text] [Related]
53. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
van der Heijde D; Kartman CE; Xie L; Beattie S; Schlichting D; Mo D; Durez P; Tanaka Y; Fleischmann R
J Rheumatol; 2022 Feb; 49(2):133-141. PubMed ID: 34526397
[TBL] [Abstract][Full Text] [Related]
54. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
55. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.
Weng HH; Ranganath VK; Khanna D; Oh M; Furst DE; Park GS; Elashoff DA; Sharp JT; Gold RH; Peter JB; Paulus HE;
J Rheumatol; 2010 Mar; 37(3):550-7. PubMed ID: 20110517
[TBL] [Abstract][Full Text] [Related]
56. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
[TBL] [Abstract][Full Text] [Related]
57. Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.
Keystone EC; Anisfeld A; Ogale S; Devenport JN; Curtis JR
J Rheumatol; 2014 Feb; 41(2):216-26. PubMed ID: 24429164
[TBL] [Abstract][Full Text] [Related]
58. Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions.
Karpouzas GA; Ormseth SR; Hernandez E; Budoff MJ
Arthritis Rheumatol; 2020 Sep; 72(9):1467-1475. PubMed ID: 32319221
[TBL] [Abstract][Full Text] [Related]
59. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
60. Correlation of single time-point damage scores with observed progression of radiographic damage during the first 6 years of rheumatoid arthritis.
Paulus HE; Oh M; Sharp JT; Gold RH; Wong WK; Park GS; Bulpitt KJ;
J Rheumatol; 2003 Apr; 30(4):705-13. PubMed ID: 12672187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
